ILC Dover is a global leader in the design and production of engineered flexible solutions, primarily serving the pharmaceutical and biopharmaceutical industries. The company specializes in creating high-performance flexible materials that are used in a variety of applications, including aerospace, medical, and inflatables markets. ILC Dover's core products include flexible isolator technology for pharmaceutical processing, which ensures superior powder flow and zero cleaning requirements, and the DoverPac for HPAPI transfers. The company operates in a niche market, providing containment solutions that protect the entire life sciences value chain, from upstream to downstream powder processing in facilities, labs, and plants.

ILC Dover's business model revolves around the development, engineering, and manufacturing of these specialized products. The company generates revenue by selling its innovative containment solutions to a diverse range of clients, including those in the pharmaceutical, biopharmaceutical, healthcare, chemical, personal care, food and beverage, aerospace, industrial, and government sectors. The recent acquisition of KSE Scientific has further expanded ILC Dover's capabilities, allowing it to offer water for injection and related solutions for biopharma, cell gene therapy, tissue banking, and medical device end markets.

Keywords: flexible solutions, pharmaceutical, biopharmaceutical, containment, isolator technology, HPAPI transfers, high-performance materials, life sciences, KSE Scientific, engineered products.